12/17/2012

Biocartis has secured $45 million in a Series D funding round, which it aims to use to increase its menu of cancer assays that run on the Apollo molecular diagnostics system. The Apollo platform, which the Swiss company purchased from Philips two years ago, is set to be introduced in Europe next year.

Related Summaries